Cybin develops tryptamine-based psychedelic therapeutics using proprietary drug discovery platforms and controllable drug delivery systems to treat mental health conditions such as Major Depressive Disorder and Generalized Anxiety Disorder. The company aims to provide safe and effective treatment options that address the unmet needs of patients suffering from these disorders.
Funding
$150M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
DTFounders
Product
Problem
Current treatments for mental health conditions like Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD) often fail to provide adequate relief or have undesirable side effects. There remains a significant unmet need for safe, effective, and rapidly acting therapies that can address the underlying biology of these disorders.
Solution
Cybin is a biopharmaceutical company focused on developing novel tryptamine-based therapeutics for mental health disorders. The company utilizes proprietary drug discovery platforms and innovative drug delivery systems to create improved treatment options. Cybin's approach involves engineering next-generation molecules with enhanced bioavailability and controllable drug delivery, combined with supportive facilitation training. Their lead programs, CYB003 and CYB004, target MDD and GAD, respectively, with the goal of providing lasting relief from depression and anxiety symptoms through intermittent dosing regimens.
Target Audience
The primary target audience includes individuals suffering from Major Depressive Disorder, Generalized Anxiety Disorder, and other CNS disorders, as well as psychiatrists and healthcare providers seeking innovative and effective treatment options.
Features
- Novel second-generation tryptamine-based therapies with improved bioavailability
- CYB003: A deuterated psilocin analog in Phase 3 development for Major Depressive Disorder, demonstrating rapid and sustained antidepressant effects
- CYB004: A DMT derivative with a focus on Generalized Anxiety Disorder, designed for short-duration, rapid-acting treatment
- Controllable drug delivery systems for precise dosing and optimized therapeutic outcomes
- Proprietary deuterated process for engineering patent-protected drug candidates
- EMBARK: Facilitation training program designed to support clinical approaches and promote healing
- Extensive intellectual property portfolio with over 80 granted patents and 230+ pending applications